OncoMatch/Clinical Trials/NCT05769660
A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM)
Is NCT05769660 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including BEY1107 and Temozolomide for glioblastoma multiforme.
Treatment: BEY1107 · Temozolomide — This is a Phase 1 study to evaluate the maximum tolerated dose, safety and efficacy of BEY1107 in combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Glioblastoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: chemotherapy
Lab requirements
Blood counts
Patients with inadequate bone marrow function [excluded]
Kidney function
Patients with inadequate kidney function [excluded]
Liver function
Patients with inadequate liver function [excluded]
Patients with inadequate bone marrow, kidney and liver function [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05769660 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages